| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:49 UTC |
|---|
| HMDB ID | HMDB0015000 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Vardenafil |
|---|
| Description | Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP. |
|---|
| Structure | CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1 InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one | ChEBI | | Levitra | ChEBI | | 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulphonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one | Generator | | VDN | HMDB | | Trihydrate, vardenafil hydrochloride | HMDB | | Dihydrochloride, vardenafil | HMDB | | Vardenafil hydrochloride | HMDB | | Vardenafil hydrochloride anhydrous | HMDB | | Vardenafil hydrochloride trihydrate | HMDB | | Anhydrous, vardenafil hydrochloride | HMDB | | Hydrochloride anhydrous, vardenafil | HMDB | | Hydrochloride trihydrate, vardenafil | HMDB | | Hydrochloride, vardenafil | HMDB | | 1-(((3-(3,4-Dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-F)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine | HMDB | | Vardenafil dihydrochloride | HMDB |
|
|---|
| Chemical Formula | C23H32N6O4S |
|---|
| Average Molecular Weight | 488.603 |
|---|
| Monoisotopic Molecular Weight | 488.220574232 |
|---|
| IUPAC Name | 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one |
|---|
| Traditional Name | levitra |
|---|
| CAS Registry Number | 224785-90-4 |
|---|
| SMILES | CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1 |
|---|
| InChI Identifier | InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) |
|---|
| InChI Key | SECKRCOLJRRGGV-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzenesulfonamides |
|---|
| Direct Parent | Benzenesulfonamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzenesulfonamide
- Benzenesulfonyl group
- Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- N-alkylpiperazine
- 1,4-diazinane
- N-substituted imidazole
- Piperazine
- Organosulfonic acid amide
- Triazine
- 1,2,4-triazine
- Heteroaromatic compound
- Sulfonyl
- Azole
- Organosulfonic acid or derivatives
- Organic sulfonic acid or derivatives
- Imidazole
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organoheterocyclic compound
- Ether
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Organooxygen compound
- Organosulfur compound
- Organic oxide
- Organopnictogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 192 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.32 g/L | Not Available | | LogP | 1.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 225.8 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.66 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.228 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.83 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 52.1 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1418.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 169.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 169.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 153.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 75.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 416.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 440.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 183.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 880.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 401.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1567.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 291.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 321.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 258.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 215.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 75.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Vardenafil,1TMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C)N12 | 4028.0 | Semi standard non polar | 33892256 | | Vardenafil,1TMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C)N12 | 3994.3 | Standard non polar | 33892256 | | Vardenafil,1TMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C)N12 | 5714.4 | Standard polar | 33892256 | | Vardenafil,1TBDMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C(C)(C)C)N12 | 4162.0 | Semi standard non polar | 33892256 | | Vardenafil,1TBDMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C(C)(C)C)N12 | 4264.0 | Standard non polar | 33892256 | | Vardenafil,1TBDMS,isomer #1 | CCCC1=NC(C)=C2C(=O)N=C(C3=CC(S(=O)(=O)N4CCN(CC)CC4)=CC=C3OCC)N([Si](C)(C)C(C)(C)C)N12 | 5599.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Vardenafil GC-MS (Non-derivatized) - 70eV, Positive | splash10-03di-9304600000-78a6e2bde8e38b367f38 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Vardenafil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil LC-ESI-QFT , negative-QTOF | splash10-000i-0040900000-a78a646244f2fb1f6276 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil , positive-QTOF | splash10-000f-0011900000-88f62b9a8f7aec917a41 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil , positive-QTOF | splash10-0002-0092000000-cf98ecae287c01370dbc | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 35V, Negative-QTOF | splash10-052r-0000900000-9008f3921907d4675261 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 10V, Positive-QTOF | splash10-000i-0000900000-1fcc6df6cdb6126d7ef0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 40V, Positive-QTOF | splash10-055r-0091200000-d63a9cf854a198162e08 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 10V, Negative-QTOF | splash10-000i-0000900000-93d391256ac331406fac | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 40V, Positive-QTOF | splash10-0udi-1924200000-417e1644b94601dd7f35 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 20V, Positive-QTOF | splash10-000i-0000900000-b883d879992fbedff256 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 40V, Negative-QTOF | splash10-001i-0090200000-050ed3eecf1ffddad8e3 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 50V, Positive-QTOF | splash10-014i-0925000000-41aba03d13dfc7df8faf | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 40V, Positive-QTOF | splash10-000i-0413900000-e1526827ae9f58ddf244 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 20V, Negative-QTOF | splash10-052r-0000900000-e5ff9d0dc7199d2f0c84 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 10V, Negative-QTOF | splash10-000i-0000900000-e10263c8f866f8b725ea | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 35V, Positive-QTOF | splash10-000i-3100900000-665b3066495254822a6c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 30V, Positive-QTOF | splash10-000i-0000900000-3b1c3b5e3ebaf21ef591 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 20V, Negative-QTOF | splash10-000i-0000900000-99f18e7a2ea26f21682b | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 40V, Negative-QTOF | splash10-055r-0091200000-74cac0a8c4e6f18b2567 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Vardenafil 20V, Positive-QTOF | splash10-000i-0000900000-7205fafb37f359d4065d | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 10V, Positive-QTOF | splash10-000i-0002900000-c0cecdb93e99efbd369e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 20V, Positive-QTOF | splash10-01w0-3536900000-89e4ca7c7d6e6e2e281e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 40V, Positive-QTOF | splash10-02ai-5492100000-78d239c94528460e3603 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 10V, Negative-QTOF | splash10-000i-0000900000-caa7e887e43db6fbbc44 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 20V, Negative-QTOF | splash10-0570-0412900000-c93873d3bd3336545c26 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vardenafil 40V, Negative-QTOF | splash10-01ot-3900000000-b864d4adedbfa7b24b3b | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|